유전성 혈관부종(HAE) 치료제 시장, 적응증별, 약물 클래스별, 투여 경로별, 유통 채널별, 환자 연령층별 - 세계 예측(2026-2032년)

The Drugs for HAE Market was valued at USD 3.75 billion in 2025 and is projected to grow to USD 4.29 billion in 2026, with a CAGR of 12.24%, reaching USD 8.42 billion by 2032.

A concise clinical and therapeutic primer capturing hereditary angioedema pathophysiology, treatment categories, and evolving patient care priorities

Hereditary angioedema (HAE) is a rare, genetically mediated disorder characterized by episodic, nonpruritic swelling resulting from dysregulation of the kallikrein-kinin system and excess generation of the vasoactive peptide bradykinin. Clinically, HAE manifests with unpredictable attacks that can involve the extremities, face, airway, and gastrointestinal tract, posing both acute life-threat scenarios and chronic burdens on quality of life. The pathophysiology centers on either quantitative or functional deficiency of C1 esterase inhibitor or on specific defects in components that regulate kallikrein activity, which together drive bradykinin-mediated increased vascular permeability.

Therapeutic approaches divide into therapies for acute attack management and strategies for long-term prophylaxis. Acute interventions aim to resolve established swelling by interrupting kallikrein activity, blocking bradykinin receptors, or replacing deficient inhibitors. Prophylactic regimens seek to reduce attack frequency and severity through intermittent or continuous modulation of the same biological pathways. Over the past decade, treatment options have diversified to include plasma-derived and recombinant biologicals, monoclonal antibodies targeting kallikrein, and small-molecule oral agents, enabling more personalized regimens for adults and pediatric patients. As clinical practice evolves, emphasis increasingly rests on rapid access to effective acute care, safe and convenient prophylactic options, and integrated patient support to improve adherence and reduce emergency care utilization.

How scientific innovation, delivery model evolution, and payer emphasis on real world outcomes are reshaping therapeutic choices and care pathways for hereditary angioedema

The HAE treatment landscape is undergoing transformative shifts driven by scientific advances, patient preferences, and changes in care delivery. At the molecular level, innovations in monoclonal antibodies and orally available small molecules have expanded the therapeutic toolkit beyond traditional plasma-derived products, enabling new mechanisms to suppress kallikrein activity and blunt bradykinin signaling with greater selectivity. Technological refinement has also produced recombinant C1 inhibitors and subcutaneous formulations that reduce administration complexity and support at-home therapy, thereby lowering barriers to prophylaxis and improving continuity of care.

Concurrently, payers and providers are emphasizing value and real-world evidence, shifting contracting approaches toward outcomes-based arrangements and tighter formulary management. Telehealth integration and specialty pharmacy partnerships have facilitated remote initiation and ongoing monitoring, which is particularly important for rare disease populations who may be geographically dispersed. Trial design has adapted in parallel, with adaptive protocols and patient-reported outcome measures becoming more prominent to capture meaningful improvements in daily functioning. Taken together, these dynamics are reshaping clinical decision making, accelerating uptake of convenient and durable therapies, and prompting manufacturers to prioritize patient support services, real-world data collection, and differentiated delivery models to maintain competitive advantage.

Assessment of how recent United States tariff shifts have affected HAE therapeutic supply chains, pricing dynamics, and strategic sourcing approaches

The introduction of new tariff measures in the United States in 2025 created a spectrum of downstream implications for the HAE supply chain, pricing strategies, and cross-border procurement of active pharmaceutical ingredients and finished biologics. Manufacturers that rely on international raw material sourcing or contract manufacturing organizations found cost structures affected by additional duties and compliance requirements, prompting some to reassess supplier footprints and to explore greater vertical integration or nearshoring. For biologics, in particular, the cost and lead time sensitivities associated with cold-chain logistics magnified the operational impact of tariff-related administrative processes, increasing the administrative burden on importers and distributors.

Payers and contracting teams responded by scrutinizing procurement pathways and emphasizing domestic manufacturing where feasible to mitigate future policy volatility. Specialty pharmacies and hospital systems evaluated formulary implications and inventory strategies to ensure uninterrupted access for patients reliant on prophylactic regimens and on-demand therapies. Manufacturers adopted several mitigation tactics, including renegotiating supplier terms, diversifying API sources, and absorbing portions of tariff costs for flagship products to preserve clinical uptake and adherence. In parallel, regulatory engagement increased as stakeholders sought clarity on classification and duty codes for novel biologics and combination products to avoid inadvertent tariff exposure. These combined actions underscore the importance of supply chain resilience and policy foresight in sustaining access to HAE therapies amid shifting trade landscapes.

Integrated segmentation analysis revealing how indication, modality, administration route, distribution channel, and age demographics determine clinical and commercial decision making

Key segmentation insights illuminate where clinical innovation, access pathways, and commercial strategy intersect across indication types, drug classes, administration routes, distribution channels, and patient age groups. When the market is viewed through the lens of indication, therapeutic choices fall into two principal categories: acute treatment and long-term prophylaxis. Acute treatment options encompass agents that act rapidly to halt ongoing bradykinin-mediated swelling and include bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors; within the C1 inhibitors category, both plasma-derived and recombinant products play distinct clinical and logistical roles, while kallikrein inhibitors appear as monoclonal antibodies or as orally administered small molecules. Long-term prophylaxis similarly segments into C1 inhibitor-based approaches and kallikrein inhibition strategies, with each subcategory offering tradeoffs between durability of effect, administration frequency, and monitoring requirements, and with plasma-derived and recombinant formats or monoclonal and small-molecule chemistries catering to different patient and provider preferences.

Analyzing drug class segmentation reinforces the importance of modality on clinical decision making, as bradykinin receptor antagonists provide acute-phase pathway blockade whereas C1 inhibitors and kallikrein inhibitors offer both acute and prophylactic utility depending on formulation and dosing. Route of administration segmentation-spanning intravenous, oral, and subcutaneous delivery-clarifies the growing preference among patients and clinicians for convenient, self-administered modalities that reduce emergency department dependence and support adherence. Distribution channel considerations-hospital pharmacy, retail pharmacy, and specialty pharmacy-highlight variance in access pathways, with specialty pharmacies playing a pivotal role in patient education, reimbursement coordination, and home delivery, while hospital settings remain critical for acute care and intravenous administration. Finally, patient age group segmentation into adult and pediatric populations underscores distinct safety, dosing, and formulation needs, and the necessity of pediatric-specific evidence to support early intervention strategies and age-appropriate administration formats. Integrating these segmentation lenses enables a more granular approach to clinical trial design, commercial positioning, and patient support program development.

Comparative regional overview outlining how local regulatory, reimbursement, and infrastructure differences drive differentiated access strategies across global territories

Regional dynamics materially affect access, regulatory timelines, and adoption patterns for hereditary angioedema therapies, and a nuanced view is essential for global strategy. In the Americas, robust clinical trial networks, established specialty pharmacy infrastructure, and payer sophistication enable relatively rapid adoption of novel biologics and oral agents, although reimbursement negotiations and prior authorization processes can moderate uptake in certain care settings. Manufacturers often prioritize the region for launch sequencing and for building comprehensive patient support offerings that include home delivery and infusion training.

In Europe, Middle East & Africa, reimbursement variability across national systems shapes commercialization approaches; centralized approvals at supranational levels coexist with country-level health technology assessments that assess comparative effectiveness and budget impact. Procurement models and tendering practices in parts of the region can favor established suppliers or lower-cost alternatives, making evidence generation and pricing strategies critical. Regulatory harmonization efforts and greater engagement with regional patient advocacy groups are increasingly influential in improving access.

In the Asia-Pacific region, heterogeneity spans mature markets with advanced regulatory pathways and emerging markets with infrastructural constraints. Emerging economies place a high premium on affordability and local manufacturing partnerships, while advanced markets emphasize real-world evidence and alignment with regional clinical guidelines. Across the region, expanding clinical trial activity and growing specialist capacity present opportunities for scaled registries and post-marketing data collection to support long-term safety and comparative effectiveness assessments. Strategic regional differentiation in manufacturing, pricing, and evidence generation is therefore central to successful, equitable access.

How corporate strategies and capability investments in manufacturing, evidence generation, and patient services shape competitive advantage within hereditary angioedema therapeutics

Company strategies in the HAE space reflect a balance between sustaining legacy biologic franchises and investing in next-generation modalities that promise improved convenience and differentiated mechanisms of action. Large biopharmaceutical companies leverage established manufacturing capabilities, clinician relationships, and distribution networks to maintain presence in acute and prophylactic segments, while emerging biotechnology firms prioritize nimble development of monoclonal antibodies, small molecules, and recombinant proteins to capture niche clinical advantages. Partnerships between incumbent manufacturers and smaller innovators have become common, enabling accelerated clinical development, expanded manufacturing capacity, and shared commercialization responsibilities.

Across the industry, emphasis on differentiated patient services has become a competitive axis, with successful companies integrating education, adherence support, and reimbursement navigation into their go-to-market models. Investment in cold-chain logistics and biologics manufacturing scale is particularly important for companies supplying plasma-derived or recombinant C1 inhibitors, while developers of oral kallikrein inhibitors focus on establishing strong safety datasets and ease-of-use messaging. Corporate strategies also include targeted labeling expansions for pediatric populations and lifecycle management through novel formulations or delivery systems. Overall, capability in evidence generation, manufacturing resiliency, and payer engagement distinguishes market leaders from smaller entrants seeking to displace incumbents via clinical differentiation or cost advantages.

Practical strategic actions that manufacturers and stakeholders can implement to secure supply resilience, demonstrate differentiated value, and improve patient outcomes in HAE care

To capture clinical and commercial value in the evolving HAE landscape, industry leaders should adopt an integrated set of strategic actions focused on resilience, differentiation, and patient centricity. First, diversify sourcing and manufacturing footprints to reduce exposure to regional tariff shifts and supply interruptions; nearshoring critical biologics production and securing multiple API suppliers will improve continuity. Second, prioritize development and commercialization of patient-friendly formulations-such as subcutaneous or oral options-to expand prophylaxis uptake and improve adherence, while concurrently investing in robust pediatric evidence to support broader labeling.

Third, strengthen relationships with specialty pharmacies and expand digital patient support platforms that combine education, adherence reminders, and remote monitoring to reduce acute care reliance and demonstrate real-world value. Fourth, engage early and proactively with payers and health technology assessment bodies to align clinical trial endpoints with payer expectations and to explore outcomes-based contracting where appropriate. Fifth, invest in post-market safety and effectiveness studies and in registries that capture long-term outcomes across diverse patient populations, thereby reinforcing value propositions. Finally, incorporate scenario planning for trade and regulatory shifts into commercial forecasts and pricing strategies, ensuring agility in contracting and the ability to respond to policy changes without disrupting patient access. Together, these actions position companies to deliver clinically meaningful advances while safeguarding supply and commercial viability.

Methodology overview describing how clinical, regulatory, expert, and supply chain evidence were synthesized to generate actionable insights for stakeholders

This analysis synthesizes evidence from clinical literature, regulatory filings, trial registries, expert consultations, and supply chain assessments to provide a multidimensional view of the HAE therapeutic environment. Primary inputs included structured interviews with clinicians specializing in immunology and allergy, pharmacy leaders experienced in specialty product distribution, and payer representatives familiar with rare disease reimbursement frameworks. Secondary sources encompassed peer-reviewed studies on pathophysiology and comparative efficacy, regulatory approval documents, and published guidance on rare disease management to triangulate clinical and policy signals.

Supply chain and tariff impact assessments combined customs and trade classification analysis with stakeholder reporting from manufacturers and distributors to evaluate operational implications. Competitive and company capability insights were derived from public disclosures, pipeline tracking, and synthesis of partnership and licensing activity. Where relevant, patient advocacy perspectives were included to capture real-world access barriers and priorities. Throughout, methodological rigor was maintained via cross-validation of inputs, explicit documentation of assumptions, and transparent acknowledgment of data limitations, particularly where proprietary commercial terms or unpublished trial datasets were not accessible. This layered approach ensures balanced, actionable conclusions while recognizing the evolving nature of clinical evidence and policy environments.

Concluding perspective on how coordinated innovation, evidence generation, and operational resilience can convert therapeutic advances into sustained improvements in patient care

The hereditary angioedema therapeutic arena is at an inflection point where biologic innovation, convenient administration formats, and evolving payer expectations intersect to create new opportunities and operational challenges. Clinical progress has yielded more targeted mechanisms to prevent and treat attacks, and advancements in delivery have made prophylaxis more accessible outside institutional settings. At the same time, external pressures such as trade policy adjustments, reimbursement complexity, and regional heterogeneity in access require manufacturers and care providers to be more strategic about manufacturing, pricing, and evidence generation.

Looking ahead, stakeholders who align product development with patient preferences, invest in resilient supply chains, and build robust real-world evidence frameworks will be best positioned to deliver meaningful clinical benefits while sustaining commercial viability. Collaboration across manufacturers, specialty pharmacies, and payers to streamline access and to demonstrate outcomes in routine practice will be essential for translating therapeutic advances into better patient experiences and reduced acute care burden. In sum, coordinated, evidence-driven action is required to ensure that innovation in HAE therapy translates into durable improvements in patient health and health system efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for HAE Market, by Indication Type

• 8.1. Acute Treatment
  • 8.1.1. Bradykinin Receptor Antagonists
  • 8.1.2. C1 Inhibitors
  • 8.1.3. C1 Inhibitors
    • 8.1.3.1. Plasma Derived
    • 8.1.3.2. Recombinant
  • 8.1.4. Kallikrein Inhibitors
    • 8.1.4.1. Monoclonal
    • 8.1.4.2. Small Molecule
• 8.2. Long Term Prophylaxis
  • 8.2.1. C1 Inhibitors
    • 8.2.1.1. Plasma Derived
    • 8.2.1.2. Recombinant
  • 8.2.2. Kallikrein Inhibitors
    • 8.2.2.1. Monoclonal
    • 8.2.2.2. Small Molecule

9. Drugs for HAE Market, by Drug Class

• 9.1. Bradykinin Receptor Antagonists
• 9.2. C1 Inhibitors
  • 9.2.1. Plasma Derived
  • 9.2.2. Recombinant
• 9.3. Kallikrein Inhibitors
  • 9.3.1. Monoclonal
  • 9.3.2. Small Molecule

10. Drugs for HAE Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Subcutaneous

11. Drugs for HAE Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Retail Pharmacy
• 11.3. Specialty Pharmacy

12. Drugs for HAE Market, by Patient Age Group

• 12.1. Adult
• 12.2. Pediatric

13. Drugs for HAE Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Drugs for HAE Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Drugs for HAE Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Drugs for HAE Market

17. China Drugs for HAE Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. ADARx Pharmaceuticals, Inc.
• 18.6. Arrowhead Pharmaceuticals, Inc.
• 18.7. Astria Therapeutics, Inc.
• 18.8. Attune Pharmaceuticals, Inc.
• 18.9. BioCryst Pharmaceuticals, Inc.
• 18.10. BioMarin Pharmaceutical Inc.
• 18.11. CSL Behring LLC
• 18.12. Grifols, S.A.
• 18.13. Intellia Therapeutics, Inc.
• 18.14. Ionis Pharmaceuticals, Inc.
• 18.15. KalVista Pharmaceuticals, Inc.
• 18.16. Pharming Group N.V.
• 18.17. Pharvaris N.V.
• 18.18. Regeneron Pharmaceuticals, Inc.
• 18.19. Sanofi S.A.
• 18.20. Swedish Orphan Biovitrum AB
• 18.21. Takeda Pharmaceutical Company Limited
• 18.22. Teva Pharmaceuticals Industries Ltd.